
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc., a regenerative medicine company, has demonstrated solid operational results, which are expected to enhance its valuation amidst mixed market dynamics related to reimbursement changes. For CY2026, the finalized reimbursement rate for their products has seen a slight increase, suggesting potential for improved financial performance and operating profit as the company capitalizes on a consolidating market. The company's extensive product portfolio and underpenetrated market opportunity present a favorable growth trajectory, positioning Organogenesis for future gains.
Bears say
Organogenesis Holdings Inc faces a negative outlook primarily due to anticipated challenges in revenue growth stemming from lower-than-expected performance of its PuraPly product line and pricing pressures on amniotic products under Medicare Part B. Additionally, the company may struggle with competitive pressures as rivals potentially integrate more efficiently and navigate regulatory hurdles, resulting in constrained market share gains. Financially, the prospect of reduced sales forces may lead to decreased commissions and a subsequent impact on the company's profitability, exacerbated by increased R&D expenditures and extended timelines for regulatory clearances for new product initiatives.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares